The legal action centers on claims that Ardelyx provided overly optimistic revenue guidance for its primary drugs, IBSRELA and XPHOZAH. While management publicly touted confidence in meeting long-term growth targets, the lawsuit contends the company concealed mounting payer-related reimbursement barriers and increasingly stringent authorization requirements. These internal challenges reportedly delayed prescription fulfillment and stunted new-patient acquisition, keeping the market in the dark regarding the true state of the company's commercial performance.
Ardelyx Faces Class Action Over Alleged Misleading Growth Forecasts
Investors who purchased Ardelyx, Inc. stock between January 13, 2025, and August 6, 2026, are now eligible to join a class action lawsuit filed by Robbins LLP. The complaint alleges the pharmaceutical company masked significant commercial hurdles, leading to an 18% share price drop following the disclosure of restricted patient access.
The discrepancy surfaced on August 6, 2026, when Ardelyx slashed its full-year revenue outlook for IBSRELA and withdrew long-term guidance for XPHOZAH. The market reaction was immediate: shares plummeted from $4.87 to $4.00 in a single trading session. Investors impacted by this decline have until November 16, 2026, to apply for lead plaintiff status. Robbins LLP, which operates on a contingency fee basis, is currently coordinating the litigation as part of its broader practice in securities fraud recovery.
Comments (0)
No comments yet. Be the first!